News
2026/10/10
JeYou Pharma's AR-NTD Inhibitor Clinical Trial Application Approved
Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the clinical trial application for its self-developed AR-NTD inhibitor, the JMN-2205 tablet project, has been approved...
Details
29
2026/09
JeYou Pharma's Subsidiary Hangyu Pharmaceutical Obtains Drug Production License (Type A Certificate) and GMP Compliance Inspection Announcement
JeYou Pharmaceutical announced that its subsidiary Hangyu Pharmaceutical has successfully obtained the Drug Production License...
24
2026/09
JeYou Pharma's Subsidiary Hangyu Pharmaceutical Showcases at the 5th Global Digital Trade Expo
Hangyu Pharmaceutical showcased its commercial manufacturing capabilities in the small molecule innovative drug sector...
18
2026/09
Phase III clinical enrollment of anti-IgE monoclonal antibody independently developed by JeYou Medicine for chronic spontaneous urticaria (CSU) was completed ahead of schedule.
Today, Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the phase III clinical enrollment of the company's independently developed anti-IgE drug, oripazumab (JYB1904), for chronic spontaneous urticaria (CSU) has been completed three months ahead of schedule ...
11
2026/08
Application for initiation of clinical trials of JeYou Pharmaceuticals 'CDK4 inhibitor and CDK2-PROTAC drug candidate molecule
Shanghai JeYou Pharmaceutical Technology Co., Ltd. announced that the company's preclinical CDK4 inhibitor (JYC010145) and CDK2-PROTAC (JMKX009137) candidate drug molecules have initiated a new drug clinical trial application……
11
2026/08
mAbs, an authoritative journal in the field of antibodies, published the latest research results of Jiyu Pharmaceutical's PD1 ×IL-2β/γ triple antibody
Recently, the latest research results of Shanghai JeYou Pharmaceutical Technology Co., Ltd.(hereinafter referred to as "JeYou Pharmaceutical") independently developed……
28
2026/02
Validating a Comprehensive R&D System and Pioneering New Frontiers in Combination Therapies | Jeyou Pharma’s First Class 1 Innovative Drug, Jielemei®, Approved for Market Launch
[Introduction] Delivering significant clinical value and ushering in a new era of differentiated competition. Shanghai Jeyou Pharmaceutical Technology Co., Ltd. (hereinafter referred to as “Jeyou Pharma”) announced today that the National Medical Products Administration (NMPA) has officially approved the market launch of Jielemei® (suximerex sulfate tablets), the company’s independently developed KRAS G12C inhibitor. As the company’s first self-developed product since its inception, the approval of Jilemei® not only provides domestic patients with KRAS G12C-mutated non-small cell lung cancer with a new treatment option that is “once-daily, more effective, and more convenient,” but also signifies that Jeyou Pharma has successfully demonstrated its capabilities across the entire R&D process—from “molecular design” to “market approval”—laying a solid foundation for the differentiated advancement of its future pipeline.